Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Passive Income Stocks to Buy Right Now. <img src="https://reportify-1252068037.cos.ap-beijing.myqcloud.com/fe-static/static/media/1x1.png" alt="Johnson &amp; Johnson (NYSE:JNJ) is included among the&nbsp;15 Best Passive Income Stocks to Buy Right Now.&nbsp; On November 12, Scotiabank&#x002019;s Louise Chen began coverag&#x00200d;e of ten large-cap biopharma companies and took a positiv&#x00200d;e&#x00200d; st&#x00200c;ance&#x00200c; on the sect&#x0 ...

Core Insights - The article discusses the growing interest in passive income, particularly through dividend investing, as a means for individuals to enhance their earnings [1] - Companies that initiate regular dividends have shown to outperform the market significantly, with an average outperformance of 650 basis points in the six months following a dividend announcement [1] - Dividend payments provide stability during uncertain market conditions and high valuations, making them attractive to investors [1] Group 1: Dividend Stocks Overview - The article identifies 15 top passive income stocks, focusing on those with a market capitalization of at least $10 billion and a history of increasing dividends for at least 10 consecutive years [3] - The selected stocks are ranked based on their potential upside, with a minimum forecasted upside of 10% [3] Group 2: Johnson & Johnson (NYSE: JNJ) - Johnson & Johnson has a remarkable dividend record, having raised its payout for 63 consecutive years, demonstrating resilience despite challenges like patent expirations [9] - The company reported third-quarter sales of $24 billion, reflecting a 6.8% increase year-over-year, indicating steady growth in its pharmaceutical portfolio [9] - Johnson & Johnson is recognized for its focus on innovative medicine and MedTech, positioning itself well for future growth [10] Group 3: Cisco Systems, Inc. (NASDAQ: CSCO) - Cisco Systems has been upgraded to a Buy rating, with an upside potential of 10.11%, supported by strong operating margins and a positive outlook for fiscal year 2026 [11][12] - The company reported record revenue of $14.88 billion for fiscal Q1 2026, a 7.53% increase from the previous year, driven by demand for AI infrastructure [13] - Cisco has consistently raised its dividends for 18 years, maintaining a strong position in IT infrastructure and AI solutions [14] Group 4: Bank of America Corporation (NYSE: BAC) - Bank of America has an upside potential of 10.28% and is viewed positively by Morgan Stanley, which maintains an Overweight rating and a $70 price target [15][16] - The bank aims for a 16% to 18% return on tangible common equity, supported by steady revenue growth and a reduction in expense ratios [16] - Bank of America has invested over $5 billion in expanding its financial centers and market presence across the U.S. from 2014 to 2024 [18]

Core Insights - StubHub shares fell nearly 25%, marking the worst day since its IPO in September, due to the company's decision not to provide guidance for the current quarter [2][3] - Bristol-Myers Squibb's stock declined by 3.4% after the company announced it would halt a trial for a heart drug developed in collaboration with Johnson & Johnson [2] - Netflix shares dropped about 3% following reports that the company is preparing bids to acquire Warner Bros. Discovery [3] Stock Movements - DoorDash stock rose nearly 7%, recovering some losses after its earnings report [4] - Cidara Therapeutics saw its stock more than double in value after Merck announced a deal to acquire the company for $221.50 per share, valuing it at approximately $9.2 billion [3] - Major U.S. equity indexes showed mixed results, with the Dow Jones down 0.3%, S&P 500 up 0.5%, and Nasdaq climbing 0.8% [1]

"By enlisting the broader startup ecosystem to identify potential nominees, this year's show feels truly connected to the community it is designed to elevate. More than ever, on display at the 2025 NEVYs is the collective power of the founders, investors, and builders who make this region thrive." Post this "For 13 years, the NEVYs have celebrated the best of New England's innovation ecosystem. What's most exciting about this year's nominees is where they came from", said Ari Fine Glantz, Executive Directo ...

Core Viewpoint - Bristol Myers Squibb and Johnson & Johnson have decided to halt a late-stage trial of their experimental blood clot drug for heart attack patients following an independent review that raised concerns about the study's findings [1] Group 1 - The independent review indicated that the study did not meet its primary endpoint, leading to the decision to stop the trial [1] - The drug was being tested for its efficacy in treating heart attack patients, but the results were not favorable enough to continue [1] - This decision may impact the companies' future product pipeline and market strategies in the cardiovascular space [1]

Core Insights - The appointment of Aldo Denti to Imricor Medical Systems signifies a strategic shift in the medical technology landscape, particularly as Johnson & Johnson is in the process of spinning off its orthopedic business [2][3][5] - Johnson & Johnson's decision to separate its DePuy Synthes orthopedic division is part of a broader restructuring strategy aimed at focusing on high-growth areas such as oncology, immunology, and cardiovascular health [3][4][10] - The migration of experienced leaders like Denti from orthopedic to cardiac intervention reflects a trend of knowledge and resource redistribution within the industry, as companies seek to innovate in new technological domains [6][9][12] Group 1: Corporate Restructuring - Johnson & Johnson announced plans to spin off its DePuy Synthes orthopedic business, which generates approximately $9.2 billion in annual revenue, representing about 10% of the company's total revenue [3][4] - The spin-off is expected to be completed within 18 to 24 months, with a target for the new entity to be operational by mid-2027 [3] - This restructuring follows the earlier divestment of its consumer health business, Kenvue, indicating a strategic pivot towards six high-growth sectors [3][10] Group 2: Talent Migration - Aldo Denti's transition from Johnson & Johnson to Imricor exemplifies the movement of talent from traditional orthopedic sectors to emerging fields like cardiac intervention [6][9] - Denti's extensive experience in orthopedic management and innovation positions him as a valuable asset for Imricor, which focuses on MRI-guided electrophysiological procedures [8][12] - The shift in leadership reflects a broader trend where expertise in surgical engineering and global business is becoming a scarce resource in new technology companies [9][12] Group 3: Technological and Growth Logic - The healthcare technology sector is witnessing a shift from mechanical and material innovations to advancements in soft tissue, neural systems, and minimally invasive interventions [9][10] - Companies like Imricor are at a critical juncture, moving from research validation to global commercialization, with Denti's role expected to enhance market access and clinical education [12] - The overarching narrative suggests that the future of medical technology will be defined more by technological logic than by product lines, as the industry transitions from orthopedic to cardiac and from mechanical to intelligent solutions [13][14]

Core Viewpoint - Johnson & Johnson's recent earnings report shows strong performance with earnings and sales exceeding estimates, but the company faces challenges from product exclusivity losses and competition in certain segments [2][3][22]. Financial Performance - Q3 2025 earnings were $2.80 per share, beating the Zacks Consensus Estimate of $2.77, and reflecting a 15.7% increase year-over-year [2]. - Reported earnings, including special items, were $2.12 per share, up 91% year-over-year [2]. - Sales reached $24.0 billion, surpassing the Zacks Consensus Estimate of $23.74 billion, with a 6.8% increase from the previous year [2][3]. Sales Breakdown - Domestic sales rose 6.2% to $13.7 billion, while international sales increased 7.6% to $10.3 billion [4]. - The Innovative Medicines segment saw sales rise 6.8% to $15.56 billion, driven by key products like Darzalex and Tremfya [5][6]. - The loss of exclusivity for Stelara negatively impacted revenue growth by 640 basis points [3]. Segment Performance - Oncology sales, particularly for Darzalex, grew 21.7% to $3.67 billion, while Imbruvica sales declined 7.8% to $695 million due to competitive pressures [8][9]. - Immunology segment sales were affected by Stelara's decline of 41.3% to $1.57 billion, attributed to biosimilar competition [13]. - The MedTech segment reported sales of $8.43 billion, up 6.8%, with strong performance in cardiovascular and surgical products [18][19]. Guidance and Outlook - The company raised its 2025 sales guidance to $93.5 billion-$93.9 billion, indicating growth of 5.4%-5.9% [22]. - Adjusted earnings per share guidance remains at $10.80-$10.90, with operational growth expected to increase by 8.2%-9.2% [24]. - For 2026, J&J anticipates top-line growth exceeding 5%, driven by key products and new launches in both Innovative Medicine and MedTech segments [26][27][28]. Market Position - Johnson & Johnson holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return from the stock in the coming months [31].

Group 1 - Johnson & Johnson (NYSE: JNJ) is being highlighted as a strong investment opportunity, particularly in the high-growth pharmaceutical sector, with a focus on cancer treatments [1] - The company is divesting from non-proprietary products, such as artificial joints, to concentrate on its core pharmaceutical business [1] - Johnson & Johnson offers a yield of over 2.7%, making it an attractive option for investors looking for stable returns [1] Group 2 - Johnson & Johnson develops and sells a wide range of healthcare products, including pharmaceuticals and medical technologies, with a focus on areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2] - The company also provides surgical systems, orthopedic solutions, cardiovascular devices, and vision care products, indicating a diverse product portfolio [2]

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the largest healthcare and pharmaceutical companies globally, recently spinning off its orthopedic business to enhance its growth potential and compete with Eli Lilly [2] Group 1: Company Developments - The spinoff of the orthopedic business is expected to position Johnson & Johnson as a growth stock [2] - The FDA recently approved Caplyta for major depressive disorder, marking a significant advancement in JNJ's drug portfolio for mental health conditions [2] - Johnson & Johnson has been pioneering treatments for suicide prevention with Spravato and is now making strides in addressing major depressive disorder [2] Group 2: Market Position and Future Outlook - Jim Cramer expressed enthusiasm about JNJ's potential to deliver substantive earnings growth through its innovative drug developments [2] - Despite the positive outlook for JNJ, there is a belief that certain AI stocks may offer higher returns with limited downside risk [2]

Core Insights - November is National Alzheimer's Disease Awareness Month in the U.S., highlighting the significance of the disease and the growing relevance of disease-modifying treatments [1] - The healthcare sector, particularly companies focused on Alzheimer's, presents a compelling investment opportunity through Healthcare exchange-traded funds (ETFs) [2] Group 1: Alzheimer's Drug Innovation - Eli Lilly's drug Kisunla (donanemab) received FDA approval in July 2024, showing a 22% slowing of clinical progression in treated patients, equating to a 1.4-month delay in disease progression [5] - Biogen, in collaboration with Eisai, launched Leqembi in 2023, which also gained full FDA approval [5] - Other significant players include Johnson & Johnson, developing two Alzheimer's medicines, and AbbVie, with its investigational drug ALIA-1758 [6] Group 2: Impact on Healthcare ETFs - The success of Alzheimer's therapies is crucial for the revenue and stock performance of companies like Eli Lilly and Biogen, making them key components in many healthcare ETFs [7] - The Dow Jones U.S. Health Care Index has increased by over 9% year to date, reflecting positive momentum from stocks like Eli Lilly and Biogen [8] Group 3: Government Support and Funding - The U.S. Senate Appropriations Committee proposed a $100 million increase for Alzheimer's and dementia research at the NIH for fiscal year 2026, indicating sustained government commitment to the biopharma sector [9] Group 4: Recommended Healthcare ETFs - Vanguard Health Care ETF (VHT) has net assets of $16.2 billion, with top holdings including Eli Lilly (10.33%) and AbbVie (5.76%), and has surged 13.4% year to date [10][11] - First Trust NASDAQ Pharmaceuticals ETF (FTXH) has net assets of $18.9 million, with top holdings including AbbVie (7.14%) and Johnson & Johnson (7.07%), rising 18.2% year to date [12] - Health Care Select Sector SPDR ETF (XLV) has assets worth $38.79 billion, with Eli Lilly (14.36%) and Johnson & Johnson (8.53%) as top holdings, increasing by 12.6% year to date [13] - iShares Neuroscience and Healthcare ETF (IBRN) has net assets of $4.38 million, with Biogen (4.04%) among its top holdings, and has surged 15.1% year to date [14]